|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14,503.00 GBX | -1.03% |
|
-3.80% | +5.25% |
| 05:22pm | Shares down as Middle East tensions rise | AN |
| 10:18am | Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7% | MT |
| Capitalization | 306B 263B 237B 227B 415B 28,088B 428B 2,796B 1,120B 13,466B 1,148B 1,123B 48,215B | P/E ratio 2026 * |
24.8x | P/E ratio 2027 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise value | 324B 278B 252B 241B 440B 29,771B 454B 2,963B 1,187B 14,273B 1,216B 1,191B 51,103B | EV / Sales 2026 * |
5.16x | EV / Sales 2027 * | 4.73x |
| Free-Float |
96.62% | Yield 2026 * |
1.69% | Yield 2027 * | 1.8% |
Last Transcript: AstraZeneca PLC
| 1 day | -1.03% | ||
| 1 week | -3.80% | ||
| Current month | -6.61% | ||
| 1 month | -2.05% | ||
| 3 months | +6.75% | ||
| 6 months | +21.40% | ||
| Current year | +5.25% |
| 1 week | 14,015.91 |  | 15,210 |
| 1 month | 14,015.91 | | 15,732 |
| Current year | 13,268 | | 15,732 |
| 1 year | 9,573.5 | | 15,732 |
| 3 years | 9,461 | | 15,732 |
| 5 years | 6,899.8 | | 15,732 |
| 10 years | 3,680 | | 15,732 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 01/10/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 01/08/2021 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 06/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 01/10/2012 |
Philip Broadley
BRD | Director/Board Member | 65 | 27/04/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.27% | 8.29% | 64 M€ | |
| -1.45% | 5.39% | 1,387 M€ | |
| -1.55% | 5.17% | 26 M€ | |
| +5.35% | 4.89% | 1,127 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.03% | -3.80% | +26.43% | +35.82% | 306B | |
| -0.70% | -0.63% | +20.68% | +217.87% | 895B | |
| +0.46% | -1.23% | +45.32% | +60.75% | 587B | |
| -0.19% | -2.93% | +4.78% | +51.63% | 401B | |
| -1.36% | -8.05% | +11.26% | +24.84% | 345B | |
| -0.53% | -5.03% | +26.71% | +62.29% | 300B | |
| -0.02% | -2.29% | +22.95% | +8.73% | 289B | |
| -0.41% | -0.42% | +14.68% | +64.76% | 202B | |
| +1.32% | +0.49% | +26.75% | +86.87% | 184B | |
| +0.56% | +0.92% | -53.31% | -49.65% | 171B | |
| Average | -0.11% | -1.14% | +14.63% | +56.39% | 368.14B | |
| Weighted average by Cap. | -0.09% | -1.51% | +19.68% | +84.93% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 62.81B 53.93B 48.75B 46.68B 85.25B 5,769B 87.94B 574B 230B 2,766B 236B 231B 9,902B | 66.81B 57.37B 51.86B 49.66B 90.69B 6,137B 93.55B 611B 245B 2,942B 251B 245B 10,534B |
| Net income | 12.5B 10.74B 9.71B 9.29B 16.97B 1,148B 17.51B 114B 45.77B 551B 46.93B 45.93B 1,971B | 14.18B 12.18B 11.01B 10.54B 19.25B 1,302B 19.85B 130B 51.91B 624B 53.22B 52.09B 2,236B |
| Net Debt | 18.32B 15.73B 14.22B 13.62B 24.87B 1,683B 25.65B 167B 67.06B 807B 68.76B 67.3B 2,888B | 10.27B 8.82B 7.97B 7.63B 13.93B 943B 14.37B 93.85B 37.58B 452B 38.53B 37.71B 1,619B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/03/26 | 14,516.00 p | -0.94% | 105,278 |
| 10/03/26 | 14,654.00 p | +1.47% | 3,182,286 |
| 09/03/26 | 14,442.00 p | -0.40% | 3,031,335 |
| 06/03/26 | 14,500.00 p | -1.85% | 1,757,450 |
| 05/03/26 | 14,774.00 p | -2.08% | 2,368,549 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition